Human Genome Sciences, Inc. Common Stock, par value $0.01 per share Underwriting Agreement
Exhibit 1.1
EXECUTION COPY
Human Genome Sciences, Inc.
Common Stock, par value $0.01 per share
July 28, 2009
Citigroup Global Markets Inc.
Xxxxxxx, Xxxxx & Co.,
Xxxxxxx, Xxxxx & Co.,
As Representatives of the several Underwriters named in Schedule I hereto, |
c/o Citigroup Global Markets Inc.
000 Xxxxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
000 Xxxxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Xxxxxxx, Sachs & Co.
00 Xxxxx Xxxxxx,
Xxx Xxxx, Xxx Xxxx 00000
00 Xxxxx Xxxxxx,
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Human Genome Sciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the
terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I
hereto (the “Underwriters”) an aggregate of 23,215,000 shares (the “Firm Shares”) and, at the
election of the Underwriters, up to 3,482,250 additional shares (the “Optional Shares”) of common
stock, par value $0.01 per share (“Common Stock”) of the Company (the Firm Shares and the Optional
Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively
called the “Shares”).
1. The Company represents and warrants to, and agrees with, each of the Underwriters that:
(a) A registration statement on Form S-3 (File No. 333-155769) (the “Initial
Registration Statement”) in respect of the Shares has been filed with the Securities and
Exchange Commission (the “Commission”); the Initial Registration Statement and any
post-effective amendment thereto, each in the form heretofore delivered to you and,
excluding exhibits to the Initial Registration Statement, but including all documents
incorporated by reference in the prospectus included therein, to you for each of the other
Underwriters have been declared effective by the Commission in such form; other than a
registration statement, if any, increasing the size of the offering (a “Rule 462(b)
Registration Statement”), filed pursuant to Rule 462(b) under the Securities Act of 1933, as
amended (the “Securities Act”), which became effective upon filing, no other document with
respect to the Initial Registration Statement or document incorporated by
reference therein has heretofore been filed, or transmitted for filing, with the
Commission (other than prospectuses filed pursuant to Rule 424(b) of the rules and
regulations of the Commission under the Securities Act, each in the form heretofore
delivered to the Representatives); and no stop order suspending the effectiveness of the
Initial Registration Statement, any post-effective amendment thereto or any part thereof or
the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that
purpose has been initiated or threatened by the Commission (the base prospectus filed as
part of the Initial Registration Statement, in the form in which it has most recently been
filed with the Commission on or prior to the date of this Agreement relating to the Shares,
is hereinafter called the “Basic Prospectus”; any preliminary prospectus (including any
preliminary prospectus supplement) relating to the Shares filed with the Commission pursuant
to Rule 424(b) under the Securities Act is hereinafter called a “Preliminary Prospectus”;
the various parts of the Initial Registration Statement and the Rule 462(b) Registration
Statement, if any, including all exhibits thereto and including any prospectus supplement
relating to the Shares that is filed with the Commission and deemed by virtue of Rule 430B
under the Securities Act to be part of the Initial Registration Statement, each as amended
at the time such part of the Initial Registration Statement became effective or such part of
the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective, are
hereinafter collectively called the “Registration Statement”; the Basic Prospectus, as
amended and supplemented immediately prior to the Applicable Time (as defined in Section
1(c) hereof), is hereinafter called the “Pricing Prospectus”; the form of the final
prospectus relating to the Shares filed with Commission pursuant to Rule 424(b) under the
Securities Act in accordance with Section 5(a) hereof is hereinafter called the
“Prospectus”; any reference herein to the Basic Prospectus, the Pricing Prospectus, any
Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the
documents incorporated by reference therein pursuant to Item 12 of Form S-3, as of the date
of such prospectus; any reference to any amendment or supplement to the Basic Prospectus,
any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any
post-effective amendment to the Registration Statement, any prospectus supplement relating
to the Shares filed with the Commission pursuant to Rule 424(b) under the Securities Act and
any documents filed under the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and incorporated therein, in each case after the date of the Basic Prospectus, such
Preliminary Prospectus or the Prospectus, as the case may be; any reference to any amendment
to the Registration Statement shall be deemed to refer to and include any annual report of
the Company filed pursuant to Section 13(a) or 15(d) of the Exchange Act after the effective
date of the Registration Statement that is incorporated by reference in the Registration
Statement; and any “issuer free writing prospectus” as defined in Rule 433 under the
Securities Act relating to the Shares is hereinafter called an “Issuer Free Writing
Prospectus”).
(b) No order preventing or suspending the use of any Preliminary Prospectus or any
Issuer Free Writing Prospectus has been issued by the Commission, and each Preliminary
Prospectus, at the time of filing thereof, conformed in all material respects to the
requirements of the Securities Act and the rules and regulations of the Commission
thereunder, and did not contain an untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in
the light of the circumstances under which they were made, not misleading; provided,
however, that this representation and warranty shall not apply to any statements or
omissions made in reliance upon and in conformity with information furnished in writing to
the Company by an Underwriter through the Representatives expressly for use therein.
2
(c) For the purposes of this Agreement, the “Applicable Time” is 6:00 p.m. (New York
City time) on the date of this Agreement. The Pricing Prospectus, as of the Applicable Time,
did not include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; and each Issuer Free Writing Prospectus listed on
Schedule II(a) hereto does not conflict with the information contained in the Registration
Statement, the Pricing Prospectus or the Prospectus and each such Issuer Free Writing
Prospectus, as supplemented by and taken together with the Pricing Prospectus as of the
Applicable Time, did not include any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to statements or omissions made in an Issuer
Free Writing Prospectus in reliance upon and in conformity with information furnished in
writing to the Company by an Underwriter through the Representatives expressly for use
therein.
(d) At the earliest time after the filing of the Registration Statement that the
Company or another offering participant made a bona fide offer (within the meaning of Rule
164(h)(2) under the Securities Act) of the Shares, the Company was not an “ineligible
issuer” as defined in Rule 405 under the Securities Act.
(e) The documents incorporated by reference in the Registration Statement, the Pricing
Prospectus or the Prospectus, when such incorporated documents became effective or were
filed with the Commission, as the case may be, conformed in all material respects to the
requirements of the Securities Act or the Exchange Act, as applicable, and the rules and
regulations thereunder, and none of such incorporated documents contained an untrue
statement of a material fact or omitted to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading; and any further documents so filed and incorporated by
reference in the Registration Statement, the Prospectus or any further amendment or
supplement thereto, when such documents become effective or are filed with the Commission,
as the case may be, will conform in all material respects to the requirements of the
Securities Act or the Exchange Act, as applicable, and the rules and regulations of the
Commission thereunder and will not contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements
therein not misleading; and no such documents were filed with the Commission since the
Commission’s close of business on the business day immediately prior to the date of this
Agreement and prior to the execution of this Agreement, except as set forth on Schedule
II(b) hereto.
(f) The Registration Statement and Preliminary Prospectus conform, and the Prospectus
and any further amendments or supplements to the Registration Statement and the Prospectus
will conform, in all material respects to the requirements of the Securities Act and the
Exchange Act, as applicable and the rules and regulations of the Commission under such Acts
and do not and will not, as of the applicable effective date and each Time of Delivery (as
defined below) as to each part of the Registration Statement and as of the applicable filing
date of the Prospectus and any amendment or supplement thereto, contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or
necessary to make the statements therein not misleading; provided, however, that this
representation and warranty shall not apply to any statements or omissions made in reliance
upon and in conformity with information furnished in writing to the Company by an
Underwriter through the Representatives expressly for use therein.
3
(g) Neither the Company nor any of its subsidiaries has sustained since the date of the
latest audited financial statements included or incorporated by reference in the Pricing
Prospectus, any material loss or interference with its business from fire, explosion, flood
or other calamity, whether or not covered by insurance, or from any labor dispute or court
or governmental action, order or decree, otherwise than as set forth or contemplated in the
Pricing Prospectus; and since the respective dates as of which information is given in the
Registration Statement and the Pricing Prospectus, there has not been (w) any material
change in the capital stock of the Company or any of its subsidiaries (other than issuances
or other transfers of capital stock in the ordinary course of business pursuant to the
Company’s employee benefit plans or stock repurchases made in connection with stock
repurchase plans), (x) any material increase in the long-term debt of the Company and its
subsidiaries, (y) since the date of the latest audited financial statements included in the
Pricing Prospectus, there has been no material adverse change, nor any development or event
involving a prospective material adverse change, in the condition (financial or other),
business, business prospects, properties or results of operations of the Company or (z) any
dividend or distribution of any kind declared, paid or made by the Company on any class of
its capital stock.
(h) The Company has been duly incorporated and is existing as a corporation in good
standing under the laws of the State of Delaware, with the requisite corporate power and
authority to own, lease and operate its properties and conduct its business as described in
the Pricing Prospectus and the Prospectus; and the Company is duly qualified to do business
as a foreign corporation in good standing in all other jurisdictions in which its ownership
or lease of property or the conduct of its business requires such qualification, except
where the failure to so qualify or to be in good standing would not or could not reasonably
be expected to have a material adverse effect on the condition (financial or otherwise),
business, business prospects, properties or results of operations of the Company and its
subsidiaries, taken as a whole (a “Material Adverse Effect”).
(i) Each subsidiary of the Company has been duly organized and is validly existing as a
corporation or other entity in good standing under the laws of the jurisdiction of its
incorporation or organization, has corporate or other power and authority to own, lease and
operate its properties and to conduct its business as described in the Pricing Prospectus,
and the Prospectus and is duly qualified as a foreign corporation to transact business and
is in good standing in each jurisdiction in which such qualification is required, whether by
reason of the ownership or leasing of property or the conduct of business, except where the
failure to so qualify or to be in good standing would not or could not reasonably be
expected to have a Material Adverse Effect.
(j) This Agreement has been duly authorized, executed and delivered by the Company.
(k) The Company has an authorized capitalization as set forth in the Pricing Prospectus
and the Prospectus and all of the issued shares of capital stock of the Company have been
duly authorized and validly issued and are fully paid and non-assessable and conform to the
description of the capital stock contained in the Pricing Prospectus and Prospectus; and all
of the issued shares of capital stock of each subsidiary of the Company have been duly
authorized and validly issued, are fully paid and non-assessable and are owned directly or
indirectly by the Company, free and clear of all liens, encumbrances, equities or claims
(“Liens”). None of the shares of capital stock of the Company or its subsidiaries were
issued in violation of preemptive or other
4
similar rights of any securityholder. The stockholders of the Company have no
preemptive rights with respect to the Shares.
(l) The Company (i) has the requisite corporate power and authority to execute and
deliver this Agreement and to perform its obligations hereunder; and (ii) has duly taken
all necessary corporate action to authorize the offering and sale of the Shares, the
execution, delivery and performance of this Agreement and the compliance with the provisions
hereof and the consummation of the transactions contemplated hereby.
(m) The Shares have been duly authorized and, when issued and delivered upon payment
therefor by the Underwriters in accordance with this Agreement, will be duly authorized and
validly issued and fully paid and non-assessable and will be free and clear of any Liens and
conform or will conform in all material respects to the description of the Common Stock
contained in the Pricing Prospectus and the Prospectus. Upon issuance, the Shares will be
duly listed, and admitted and authorized for trading on Nasdaq Stock Market LLC (“Nasdaq”).
(n) The statements set forth in the Pricing Prospectus and Prospectus, under the
caption “Description of Common Stock and Preferred Stock”, insofar as they are descriptions
of contracts, agreements or other legal documents or describe the applicable statutes, rules
and regulations, constitute an accurate summary of the matters set forth therein in all
material respects.
(o) The Company is not and, after giving effect to the offering and sale of the Shares
and the application of the proceeds thereof, will not be an “investment company”, as such
term is defined in the Investment Company Act of 1940, as amended (the “Investment Company
Act”).
(p) No consent, approval, authorization, or order of, or filing with, any governmental
agency or body or any court is required in connection with the offering and sale of the
Shares, for the execution, delivery and performance by the Company of this Agreement or in
connection with the transactions contemplated by this Agreement, except such as may be
required under the blue sky laws of any jurisdiction in connection with the transactions
contemplated by this Agreement.
(q) (i) The offering and sale of the Shares in accordance with the terms of this
Agreement and (ii) compliance with the terms and provisions hereof will not result in a
breach of, violation of or imposition of any Lien upon any material property or assets of
the Company or any of its subsidiaries pursuant to, any of the terms and provisions of, or
constitute a default under, any statute, any rule, regulation or order of any governmental
agency or body or any court or other authority, domestic or foreign, having jurisdiction
over the Company, or any of its subsidiaries, or any of their properties, or any material
agreement or instrument to which the Company or any of its subsidiaries is a party or by
which the Company or any of its subsidiaries is bound or to which any of the material
properties of the Company or any of its subsidiaries is subject, or the certificate of
incorporation or by-laws of the Company or any of its subsidiaries. The Company has full
corporate power and authority to authorize, issue and sell the Shares as contemplated by
this Agreement.
(r) The financial statements and schedules incorporated by reference in the Pricing
Prospectus and the Prospectus, and the Registration Statement present fairly the financial
position of the Company as of the dates shown and their results of operations
5
and cash flows for the periods shown, comply as to form in all material respects with
the applicable accounting requirements of the Securities Act and such financial statements
have been prepared in conformity with generally accepted accounting principles in the United
States applied on a consistent basis.
(s) Except as disclosed in the Pricing Prospectus and the Prospectus, there are no
pending actions, suits or proceedings against or affecting the Company or any of its
properties that, if determined adversely to the Company, would individually or in the
aggregate have a Material Adverse Effect or would materially and adversely affect the
ability of the Company to perform its obligations under this Agreement; and no such actions,
suits or proceedings are, to the Company’s knowledge, threatened or contemplated.
(t) No labor disputes with the employees of the Company or any of its subsidiaries
exist or, to the knowledge of the Company, are imminent that would have a Material Adverse
Effect.
(u) Neither the Company nor any subsidiary is in violation or default of (i) any
provision of its certificate of incorporation or by-laws, (ii) the terms of any indenture,
contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement,
obligation, condition, covenant or instrument to which it is a party or bound or to which
its property is subject or (iii) any statute, law, rule, regulation, judgment, order or
decree of any court, regulatory body, administrative agency, governmental body, arbitrator
or other authority applicable to or having jurisdiction over the Company or such subsidiary
or any of its properties, as applicable, which violation or default would, in the case of
clauses (ii) and (iii) above, either individually or in the aggregate with all other
violations and defaults referred to in this paragraph, reasonably be expected to result in a
Material Adverse Effect.
(v) The clinical, pre-clinical and other studies and tests conducted by or on behalf of
or sponsored by the Company that are described in the Pricing Prospectus and the Prospectus
or the results of which are referred to in the Pricing Prospectus and the Prospectus were
and, if still pending, are being conducted in accordance, in all material respects, with
standard medical and scientific research procedures and all applicable federal, state, local
and foreign laws, rules and regulations, including without limitation those of the U.S. Food
& Drug Administration (the “FDA”); the descriptions in the Pricing Prospectus and the
Prospectus of the results of such studies and tests are accurate and complete in all
material respects and fairly present the data derived from such studies and tests; except to
the extent disclosed in the Pricing Prospectus and the Prospectus, the Company has operated
and currently is in compliance in all material respects with all applicable rules,
regulations and policies, including without limitation those of the FDA and comparable drug
regulatory agencies outside of the United States (collectively, the “Regulatory
Authorities”); and except to the extent disclosed in the Pricing Prospectus and the
Prospectus, the Company has not received any notices or other correspondence from the
Regulatory Authorities or any other governmental agency requiring the termination,
suspension, delay or modification of any clinical or pre-clinical study or test sponsored by
the Company, that is described in the Pricing Prospectus and the Prospectus or the results
of which are referred to in the Pricing Prospectus and the Prospectus.
(w) The Company and each of its subsidiaries carry, or are covered by, insurance in
such amounts and covering such risks as is adequate for the conduct of
6
their respective businesses and the value of their respective properties and as is
customary for companies engaged in similar businesses in similar industries.
(x) The Company and its subsidiaries possesses adequate certificates, licenses,
authorities or permits issued by appropriate governmental agencies or bodies necessary to
conduct their business, as described in the Preliminary Prospectus and Prospectus, and have
not received any notice of proceedings relating to the revocation or modification of any
such certificate, license, authority or permit that, if determined adversely to the Company
or its subsidiaries, would individually or in the aggregate have a Material Adverse Effect.
(y) Ernst & Young LLP, independent registered public accounting firm, which has audited
the consolidated financial statements of the Company and its consolidated subsidiaries, and
delivered their report with respect to audited consolidated financial statements included or
incorporated by reference in the Registration Statement, the Pricing Prospectus and the
Prospectus, is an independent registered public accounting firm as required by the
Securities Act and the rules and regulations of the Commission thereunder.
(z) The Company and each of its subsidiaries maintains a system of internal control
over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act)
sufficient to provide reasonable assurances that (A) transactions are executed in accordance
with management’s general or specific authorization; (B) transactions are recorded as
necessary to permit preparation of financial statements in conformity with generally
accepted accounting principles and to maintain accountability for assets; (C) access to
assets is permitted only in accordance with management’s general or specific authorization;
and (D) the recorded accountability for assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. The
Company’s internal control over financial reporting is effective and the Company is not
aware of any material weaknesses in its internal control over financial reporting. Since the
date of the latest audited financial statements included or incorporated by reference in the
Pricing Prospectus and the Prospectus, there has been no change in the Company’s internal
control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial reporting.
(aa) The Company maintains a system of “disclosure controls and procedures” (as such
term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements
of the Exchange Act; such disclosure controls and procedures have been designed to ensure
that material information relating to the Company and its subsidiaries is made known to the
Company’s principal executive officer and principal financial officer by others within those
entities; and such disclosure controls and procedures are effective to perform the functions
for which they were established.
(bb) The Company or any of its subsidiaries is not in violation of any statute, rule,
regulation, decision or order of any governmental agency or body or any court, domestic or
foreign, applicable to or having jurisdiction over the Company or such subsidiary or any of
its properties, as applicable, relating to the use, disposal or release of hazardous or
toxic substances or relating to the protection or restoration of the environment or human
exposure to hazardous or toxic substances (collectively, “environmental laws”), does not own
or operate any real property contaminated with any substance that is subject to any
environmental laws at levels or in quantities that could reasonably be expected to require
remediation, is not liable for any off-site disposal or contamination
7
pursuant to any environmental laws, and is not subject to any claim relating to any
environmental laws, which violation, contamination, liability or claim, in each case, is
expected, individually or in the aggregate, to have a Material Adverse Effect; and the
Company is not aware of any pending investigation which might lead to such a claim.
(cc) Except as disclosed in the Pricing Prospectus and the Prospectus, the Company and
its subsidiaries own or possess, or can acquire on reasonable terms, patents, inventions,
copyrights, know-how (including trade secrets and other unpatented and/or unpatentable
proprietary or confidential information, systems or procedures), trademarks, service marks,
trade names or other intellectual property (collectively, “Intellectual Property”) necessary
to carry on the business as described in the Pricing Prospectus and the Prospectus. Except
as disclosed in the Pricing Prospectus and the Prospectus, neither the Company nor any of
its subsidiaries has received any notice of any claim by a third party against them alleging
infringement of, interference with or any other conflict with asserted rights of others with
respect to any Intellectual Property, which (if the subject of any unfavorable decision,
ruling or finding), singly or in the aggregate, would result in a Material Adverse Effect.
(dd) At least two U.S. patents owned, assigned or licensed to the Company and at least
24 non-U.S. patents (including two European patents validated in 23 and 24 countries
respectively) owned, assigned or licensed to the Company claim the composition, use or
manufacture of BENLYSTATM; no U.S. patents owned, assigned or licensed to the
Company and no non-U.S. patents owned, assigned or licensed to the Company claim the
composition, use or manufacture of raxibacumab (ABthrax); at least two U.S. patents owned,
assigned or licensed to the Company and at least three non-U.S. patents (including one
European patent validated in 16 countries) owned, assigned or licensed to the Company claim
the composition, use or manufacture of ZALBINTM (formerly ALBUFERON®);
all such patents are being duly maintained by the Company or, to the best of the Company’s
knowledge, its licensors and are in full force and effect. In addition, there are numerous
other patent applications that claim the composition, use or manufacture of these products
and they are being diligently prosecuted by the Company, or, to the best of the Company’s
knowledge, its licensors.
(ee) Except as disclosed in the Pricing Prospectus and the Prospectus, the Company has
good and marketable title to all material real properties and all other material properties
and assets owned by it, in each case free from Liens that would materially affect the value
thereof or materially interfere with the use made or to be made thereof by the Company; and
except as disclosed in the Pricing Prospectus and the Prospectus, the Company holds any
leased real or personal property under valid and enforceable leases with no exceptions that
would materially interfere with the use made or to be made thereof by it.
(ff) The Company is in compliance in all material respects with the applicable
provisions of the Xxxxxxxx-Xxxxx Act of 2002.
(gg) There are no contracts, agreements or understandings between the Company and any
person that would give rise to a valid claim against the Company or the Underwriters for a
brokerage commission, finder’s fee or other like payment in connection with the offering and
sale of the Shares.
(hh) Neither the Company nor, to the Company’s knowledge, any affiliate (within the
meaning of Regulation M under the Securities Act) of the Company has taken, nor will the
Company or any affiliate take, directly or indirectly, any action which is designed
8
to or which has constituted or which would be expected to cause or result in
stabilization or manipulation of the price of any security of the Company to facilitate the
offering and sale of the Shares, except that no representation or warranty is made with
respect to, or in connection with, any action taken by or on behalf of, any Underwriter or
any affiliate of any of them or any of their partners, members, directors, officers,
employees or agents.
(ii) The Company is in compliance in all material respects with all presently
applicable provisions of the Employee Retirement Income Security Act of 1974, as amended,
including the regulations and published interpretations thereunder (“ERISA”); no “reportable
event” (as defined in ERISA) has occurred with respect to any “pension plan” (as defined in
ERISA) for which the Company would have any liability; the Company has not incurred and does
not currently expect to incur material liability under (A) Title IV of ERISA with respect to
the termination of, or withdrawal from, any “pension plan” or (B) Section 412 or 4971 of the
Internal Revenue Code of 1986, as amended, including the regulations and published
interpretations thereunder (the “Code”); and each “pension plan” for which the Company would
have any liability that is intended to be qualified under Section 401(a) of the Code is so
qualified in all material respects and nothing has occurred, whether by action or by failure
to act, which would cause the loss of such qualification.
(jj) The Company is subject to the reporting requirements of Section 13 or Section
15(d) of the Exchange Act. The Common Stock is registered pursuant to Section 12(b) of the
Exchange Act and is listed on Nasdaq and the Company has taken no action designed to, or
likely to have the effect of, terminating the registration of the Common Stock under the
Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any
notification that the Commission or Nasdaq is contemplating terminating such registration or
listing.
(kk) The Company has no debt securities rated by any “nationally recognized statistical
rating organization”, as that term is defined by the Commission for purposes of Rule
436(g)(2) under the Securities Act.
2. Subject to the terms and conditions herein set forth, (a) the Company agrees to issue and
sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly,
to purchase from the Company, at a purchase price per share of $13.37, the number of Firm Shares
set forth opposite the name of such Underwriter in Schedule I hereto and (b) in the event and to
the extent that the Underwriters shall exercise the election to purchase Optional Shares as
provided below, the Company agrees to issue and sell to each of the Underwriters, and each of the
Underwriters agrees, severally and not jointly, to purchase from the Company, at the purchase price
per share set forth in clause (a) of this Section 2, that portion of the number of Optional Shares
as to which such election shall have been exercised (to be adjusted by you so as to eliminate
fractional shares) determined by multiplying such number of Optional Shares by a fraction, the
numerator of which is the maximum number of Optional Shares which such Underwriter is entitled to
purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the
denominator of which is the maximum number of Optional Shares that all of the Underwriters are
entitled to purchase hereunder.
The Company hereby grants to the Underwriters the right to purchase at their election up to
2,700,000 Optional Shares, at the purchase price per share set forth in the paragraph above, for
the sole purpose of covering sales of shares in excess of the number of Firm Shares, provided that
the purchase price per Optional Share shall be reduced by an amount per share equal to any
dividends or distributions declared by the Company and payable on the Firm Shares but not payable
on the Optional Shares. Any such election to purchase Optional Shares
9
may be exercised only by written notice from you to the Company, given within a period of 30
calendar days after the date of this Agreement, setting forth the aggregate number of Optional
Shares to be purchased and the date on which such Optional Shares are to be delivered, as
determined by you but in no event earlier than the First Time of Delivery (as defined in Section 4
hereof) or, unless you and the Company otherwise agree in writing, earlier than two or later than
ten business days after the date of such notice.
3. Upon the authorization by you of the release of the Shares, the several Underwriters
propose to offer the Shares for sale upon the terms and conditions set forth in the Prospectus.
4. (a) The Shares to be purchased by each Underwriter hereunder, in definitive form, and in
such authorized denominations and registered in such names as the Representatives may request upon
at least forty-eight hours’ prior notice to the Company shall be delivered by or on behalf of the
Company to Citigroup Global Markets Inc., through the facilities of the Depository Trust Company
(“DTC”), for the account of such Underwriter, against payment by or on behalf of such Underwriter
of the purchase price therefor by wire transfer of Federal (same-day) funds to the account
specified by the Company to the Representatives at least forty-eight hours in advance. The Company
will cause the certificates representing the Shares to be made available for checking and packaging
at least twenty-four hours prior to the Time of Delivery (as defined below) with respect thereto at
the office of DTC or its designated custodian (the “Designated Office”). The time and date of such
delivery and payment shall be, with respect to the Firm Shares, 9:30 a.m. (New York City time), on
August 3, 2009 or such other time and date as the Representatives and the Company may agree upon in
writing, and, with respect to the Optional Shares, 9:30 a.m. (New York City time), on the date
specified by the Representatives in the written notice given by the Representatives of the
Underwriters’ election to purchase such Optional Shares, or such other time and date as the
Representatives and the Company may agree upon in writing. Such time and date for delivery of the
Firm Shares is herein called the “First Time of Delivery”, such time and date for delivery of the
Optional Shares, if not the First Time of Delivery, is herein called the “Second Time of Delivery”,
and each such time and date for delivery is herein called a “Time of Delivery”.
(b) The documents to be delivered at each Time of Delivery by or on behalf of the parties
hereto pursuant to Section 8 hereof, including the cross receipt for the Shares and any additional
documents requested by the Underwriters pursuant to Section 8(j) hereof, will be delivered at the
offices of Xxxxxxx Xxxxxxx & Xxxxxxxx LLP, 000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx, 00000 (the
“Closing Location”), and the Shares will be delivered at the Designated Office, all at such Time of
Delivery. A meeting will be held at the Closing Location at 2:00 p.m. (New York City time), on the
New York Business Day next preceding such Time of Delivery, at which meeting the final drafts of
the documents to be delivered pursuant to the preceding sentence will be available for review by
the parties hereto. For the purposes of this Section 4, “New York Business Day” shall mean each
Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in
New York are generally authorized or obligated by law or executive order to close.
5. The Company agrees with each of the Underwriters:
(a) To prepare the Prospectus in a form approved by you and to file such Prospectus
pursuant to Rule 424(b) under the Securities Act not later than the Commission’s close of
business on the second business day following the date of this Agreement or such earlier
time as may be required under the Securities Act; to make no further amendment or any
supplement to the Registration Statement, the Basic Prospectus or the Prospectus prior to
the last Time of Delivery which shall be
10
disapproved by you promptly after reasonable notice thereof; to advise you, promptly
after it receives notice thereof, of the time when any amendment to the Registration
Statement has been filed or becomes effective or any amendment or supplement to the
Prospectus has been filed and to furnish you with copies thereof; to file promptly all
material required to be filed by the Company with the Commission pursuant to Rule 433(d)
under the Securities Act; within the time required by such Rule; to file promptly all
reports and any definitive proxy or information statements required to be filed by the
Company with the Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus
(or in lieu thereof, the notice referred to in Rule 173(a) under the Securities Act) is
required in connection with the offering and sale of the Shares; to advise you, promptly
after it receives notice thereof, of the issuance by the Commission of any stop order or of
any order preventing or suspending the use of any Preliminary Prospectus or other prospectus
in respect of the Shares, of the suspension of the qualification of the Shares for offering
and sale in any jurisdiction, of the initiation or threatening of any proceeding for any
such purpose, or of any request by the Commission for the amending or supplementing of the
Registration Statement or the Prospectus or for additional information; and, in the event of
the issuance of any stop order or of any order preventing or suspending the use of any
Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly
use its best efforts to obtain the withdrawal of such order.
(b) Promptly from time to time to take such action as you may reasonably request to
qualify the Shares for offering and sale under the securities laws of such jurisdictions as
you may request and to comply with such laws so as to permit the continuance of sales and
dealings therein in such jurisdictions for as long as may be necessary to complete the
distribution of the Shares, provided that in connection therewith the Company shall not be
required to qualify as a foreign corporation or to file a general consent to service of
process in any jurisdiction.
(c) If by the third anniversary (the “Renewal Deadline”) of the initial effective date
of the Registration Statement, (i) any of the Shares remain unsold by the Underwriters and
(ii) such shares cannot be sold other than pursuant to an effective registration statement,
upon at least 60 days (but not more than 120 days) prior written notice, the Company will
file, if it has not already done so and is eligible to do so, a new shelf registration
statement relating to the Shares, in a form reasonably satisfactory to you and will use its
reasonable best efforts to cause such registration statement to be declared effective within
180 days after the later of (x) the Renewal Deadline and (y) the date of such notice. The
Company will take all other action necessary or appropriate to permit the public offering
and sale of the Shares to continue as contemplated in the expired registration statement
relating to the Shares. References herein to the Registration Statement shall include such
new automatic shelf registration statement or such new shelf registration statement, as the
case may be.
(d) Prior to 10:00 a.m. (New York City time), on the New York Business Day next
succeeding the date of this Agreement and from time to time, to furnish the Underwriters
with written and electronic copies of the Prospectus in New York City in such quantities as
you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the
notice referred to in Rule 173(a) under the Securities Act) is required at any time prior to
the expiration of nine months after the time of issue of the Prospectus in connection with
the offering and sale of the Shares and if at such time any event shall have occurred as a
result of which the Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state any material fact
11
necessary in order to make the statements therein, in the light of the circumstances
under which they were made when such Prospectus (or in lieu thereof, the notice referred to
in Rule 173(a) under the Securities Act) is delivered, not misleading, or, if for any other
reason it shall be necessary during such same period to amend or supplement the Prospectus
or to file under the Exchange Act any document incorporated by reference in the Prospectus
in order to comply with the Securities Act or the Exchange Act, to notify you and upon your
request to file such document and to prepare and furnish without charge to each Underwriter
and to any dealer in securities as many written and electronic copies as you may from time
to time reasonably request of an amended Prospectus or a supplement to the Prospectus which
will correct such statement or omission or effect such compliance; and in case any
Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to
in Rule 173(a) under the Securities Act) in connection with sales of any of the Shares at
any time nine months or more after the time of issue of the Prospectus, upon your request
but at the expense of such Underwriter, to prepare and deliver to such Underwriter as many
written and electronic copies as you may request of an amended or supplemented Prospectus
complying with Section 10(a)(3) of the Securities Act.
(e) To make generally available to its security holders as soon as practicable, but in
any event not later than sixteen months after the effective date of the Registration
Statement (as defined in Rule 158(c) under the Securities Act), an earnings statement of the
Company and its subsidiaries (which need not be audited) complying with Section 11(a) of the
Securities Act and the rules and regulations of the Commission thereunder (including, at the
option of the Company, Rule 158).
(f) During the period beginning from the date hereof and continuing to and including
the date 90 days after the date of the Prospectus, not to offer, sell, contract to sell,
pledge, grant any option to purchase, make any short sale or otherwise dispose, except as
provided hereunder, of any securities of the Company that are substantially similar to the
Shares, including but not limited to any options or warrants to purchase shares of Common
Stock or any securities that are convertible into or exchangeable for, or that represent the
right to receive, Common Stock or any such substantially similar securities (other than
pursuant to employee stock option plans or employee stock purchase plans each existing on,
or Common Stock issuable (at the conversion rates in effect on the date hereof) upon
exchange for, or conversion of, convertible securities outstanding as of the date of this
Agreement) without your prior written consent.
(g) If the Company elects to rely upon Rule 462(b), the Company shall file a Rule
462(b) Registration Statement with the Commission in compliance with Rule 462(b) by 10:00
p.m. (New York City time), on the date of this Agreement, and the Company shall at the time
of filing either pay the Commission the filing fee for the Rule 462(b) Registration
Statement or give irrevocable instructions for the payment of such fee pursuant to Rule
111(b) under the Securities Act.
(h) Upon request of any Underwriter, to furnish, or cause to be furnished, to such
Underwriter an electronic version of the Company’s trademarks, servicemarks and corporate
logo for use on the website, if any, operated by such Underwriter for the purpose of
facilitating the on-line offering of the Shares (the “License”); provided, however, that the
License shall be used solely for the purpose described above, is granted without any fee and
may not be assigned or transferred.
(i) To use the net proceeds received by it from the sale of the Shares in the manner
specified in the Pricing Prospectus under the caption “Use of Proceeds”.
12
(j) To use its best efforts to list, subject to notice of issuance, on Nasdaq.
6. (a) The Company represents and agrees that, without the prior consent of the
Representatives, it has not made and will not make any offer relating to the Shares that would
constitute a “free writing prospectus” as defined in Rule 405 under the Securities Act; each
Underwriter represents and agrees that, without the prior consent of the Company and the
Representatives, it has not made and will not make any offer relating to the Securities that would
constitute a free writing prospectus; any such free writing prospectus the use of which has been
consented to by the Company and the Representatives is listed on Schedule II(a) hereto.
(b) The Company has complied and will comply with the requirements of Rule 433 under the
Securities Act applicable to any Issuer Free Writing Prospectus, including timely filing with the
Commission or retention where required and legending.
(c) The Company agrees that if at any time following issuance of an Issuer Free Writing
Prospectus any event occurred or occurs as a result of which such Issuer Free Writing Prospectus
would conflict with the information in the Registration Statement, the Pricing Prospectus or the
Prospectus or would include an untrue statement of a material fact or omit to state any material
fact necessary in order to make the statements therein, in the light of the circumstances then
prevailing, not misleading, the Company will give prompt notice thereof to the Representatives and,
if requested by the Representatives, will prepare and furnish without charge to each Underwriter an
Issuer Free Writing Prospectus or other document which will correct such conflict, statement or
omission; provided, however, that this covenant and agreement shall not apply to any statements or
omissions in an Issuer Free Writing Prospectus made in reliance upon and in conformity with
information furnished in writing to the Company by an Underwriter through the Representatives
expressly for use therein.
7. The Company covenants and agrees with the several Underwriters that the Company will pay or
cause to be paid the following: (i) the fees, disbursements and expenses of the Company’s counsel
and accountants in connection with the registration of the Shares under the Securities Act and all
other expenses in connection with the preparation, printing, reproduction and filing of the
Registration Statement, the Basic Prospectus, any Preliminary Prospectus, any Issuer Free Writing
Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering
of copies thereof to the Underwriters and dealers; (ii) the cost of printing or producing any
Agreement among Underwriters, this Agreement, any Blue Sky Memorandum, closing documents (including
any compilations thereof) and any other documents in connection with the offering, purchase, sale
and delivery of the Shares; (iii) all expenses in connection with the qualification of the Shares
for offering and sale under state securities laws as provided in Section 5(b) hereof, including the
reasonable fees and disbursements of counsel for the Underwriters in connection with such
qualification and in connection with the Blue Sky survey(s); (iv) the filing fees incident to, and
the reasonable fees and disbursements of counsel for the Underwriters in connection with, any
required review by the Financial Industry Regulatory Authority of the terms of the sale of the
Shares; (v) the cost of preparing certificates for the Shares; (vi) the cost and charges of any
transfer agent or registrar; (vii) all fees and expenses in connection with listing the Shares on
Nasdaq; and (viii) all other reasonable costs and expenses incident to the performance of its
obligations hereunder which are not otherwise specifically provided for in this Section. It is
understood, however, that, except as provided in this Section, and Sections 9 and 12 hereof, the
Underwriters will pay all of their own costs and expenses, including the fees of their counsel,
transfer taxes on resale of any of the Shares by them, and any advertising expenses connected with
any offers they may make.
13
8. The obligations of the Underwriters hereunder, as to the Shares to be delivered at each
Time of Delivery, shall be subject, in their discretion, to the condition that all representations
and warranties and other statements of the Company herein are, at and as of such Time of Delivery,
true and correct, the condition that the Company shall have performed all of its obligations
hereunder theretofore to be performed, and the following additional conditions:
(a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b)
under the Securities Act within the applicable time period prescribed for such filing by the
rules and regulations under the Securities Act and in accordance with Section 5(a) hereof;
all material required to be filed by the Company pursuant to Rule 433(d) under the
Securities Act shall have been filed with the Commission within the applicable time period
prescribed for such filings by Rule 433; if the Company has elected to rely upon Rule 462(b)
under the Securities Act, the Rule 462(b) Registration Statement shall have become effective
by 10:00 p.m. (New York City time), on the date of this Agreement; no stop order suspending
the effectiveness of the Registration Statement or any part thereof shall have been issued
and no proceeding for that purpose shall have been initiated or threatened by the
Commission; no stop order suspending or preventing the use of the Prospectus or any Issuer
Free Writing Prospectus shall have been initiated or threatened by the Commission; and all
requests for additional information on the part of the Commission shall have been complied
with to your reasonable satisfaction.
(b) Xxxxxxx Xxxxxxx & Xxxxxxxx LLP, counsel for the Underwriters, shall have furnished
to you such written opinion or opinions, dated such Time of Delivery, with respect to such
matters as the Representatives may reasonably request, and such counsel shall have received
such papers and information as they may reasonably request to enable them to pass upon such
matters.
(c) (i) Xxxxx X. Xxxxx, the General Counsel of the Company, shall have furnished to you
his written opinion and disclosure letter, each dated such Time of Delivery, in form and
substance satisfactory to you, to the effect set forth in Annex I hereto, and (ii) DLA Piper
LLP (US), counsel for the Company, shall have furnished to you their written opinion and
disclosure letter, each dated such Time of Delivery, in form and substance satisfactory to
you, to the effect set forth in Annex II hereto.
(d) On the date of the Prospectus at a time prior to the execution of this Agreement,
at 9:30 a.m. (New York City time), on the effective date of any post effective amendment to
the Registration Statement filed subsequent to the date of this Agreement and also at each
Time of Delivery, Ernst & Young LLP shall have furnished to you a “comfort” letter or
letters, dated the respective dates of delivery thereof, in form and substance satisfactory
to you.
(e) (i) The Company shall not have sustained since the date of the latest audited
financial statements included or incorporated by reference in the Pricing Prospectus any
loss or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or governmental
action, order or decree, otherwise than as set forth or contemplated in the Pricing
Prospectus, and (ii) since the respective dates as of which information is given in the
Pricing Prospectus there shall not have been any change in the capital stock or long-term
debt of the Company or any change, or any development involving a prospective change, in or
affecting the general affairs, management, financial position, stockholders’ equity or
results of operations of the Company, otherwise than as set forth
14
or contemplated in the Pricing Prospectus, the effect of which, in any such case
described in clause (i) or (ii), is in your judgment so material and adverse as to make it
impracticable or inadvisable to proceed with the public offering or the delivery of the
Shares on the terms and in the manner contemplated in the Pricing Prospectus and the
Prospectus.
(g) On or after the Applicable Time there shall not have occurred any of the following:
(i) a suspension or material limitation in trading in securities generally on Nasdaq; (ii) a
suspension or material limitation in trading in the Company’s securities on Nasdaq; (iii) a
general moratorium on commercial banking activities declared by either federal or New York
State authorities or a material disruption in commercial banking or securities settlement or
clearance services in the United States; (iv) the outbreak or escalation of hostilities
involving the United States or the declaration by the United States of a national emergency
or war; or (v) the occurrence of any other calamity or crisis or any change in financial,
political or economic conditions in the United States or elsewhere, if the effect of any
such event specified in clause (iv) or (v) in your judgment makes it impracticable or
inadvisable to proceed with the public offering or the delivery of the Shares being
delivered at such Time of Delivery on the terms and in the manner contemplated in the
Pricing Prospectus and the Prospectus.
(h) The Shares at each Time of Delivery shall have been approved for listing, subject
to notice of issuance, on Nasdaq.
(i) The Company shall have complied with the provisions of Section 5(c) hereof with
respect to the furnishing of prospectuses on the New York Business Day next succeeding the
date of this Agreement.
(j) The Company shall have furnished or caused to be furnished to you at such Time of
Delivery certificates of officers of the Company satisfactory to you as to the accuracy of
the representations and warranties of the Company herein at and as of such Time of Delivery,
as to the performance by the Company of all of its obligations hereunder to be performed at
or prior to such Time of Delivery, as to the matters set forth in subsections (a) and (e) of
this Section and as to such other matters as you may reasonably request.
9. (a) The Company will indemnify and hold harmless each Underwriter against any losses,
claims, damages or liabilities, joint or several, to which such Underwriter may become subject,
under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or
actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue
statement of a material fact contained in the Registration Statement, the Basic Prospectus, any
Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement
thereto, any Issuer Free Writing Prospectus or any “issuer information” filed or required to be
filed pursuant to Rule 433(d) under the Securities Act, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse each Underwriter for
any legal or other expenses reasonably incurred by such Underwriter in connection with
investigating or defending any such action or claim as such expenses are incurred; provided,
however, that the Company shall not be liable in any such case to the extent that any such loss,
claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue
statement or omission or alleged omission made in the Registration Statement, the Basic Prospectus,
any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or
supplement thereto, or any Issuer Free
15
Writing Prospectus, in reliance upon and in conformity with written information furnished to
the Company by any Underwriter through the Representatives expressly for use therein.
(b) Each Underwriter will indemnify and hold harmless the Company against any losses, claims,
damages or liabilities to which the Company may become subject, under the Securities Act or
otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof)
arise out of or are based upon an untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the
Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free
Writing Prospectus, or arise out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein or necessary to make the statements therein
not misleading, in each case to the extent, but only to the extent, that such untrue statement or
alleged untrue statement or omission or alleged omission was made in the Registration Statement,
the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any
amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in
conformity with written information furnished to the Company by such Underwriter through the
Representatives expressly for use therein; and will reimburse the Company for any legal or other
expenses reasonably incurred by the Company in connection with investigating or defending any such
action or claim as such expenses are incurred.
(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice
of the commencement of any action, such indemnified party shall, if a claim in respect thereof is
to be made against the indemnifying party under such subsection, notify the indemnifying party in
writing of the commencement thereof; but the omission so to notify the indemnifying party shall not
relieve it from any liability which it may have to any indemnified party (except to the extent that
such failure to notify results in any material prejudice against the indemnifying party with
respect to such action) otherwise than under subsection (a) or (b). In case any such action shall
be brought against any indemnified party and it shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to participate therein and, to the
extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume
the defense thereof, with counsel satisfactory to such indemnified party (who shall not, except
with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice
from the indemnifying party to such indemnified party of its election so to assume the defense
thereof, the indemnifying party shall not be liable to such indemnified party under such subsection
for any legal expenses of other counsel or any other expenses, in each case subsequently incurred
by such indemnified party, in connection with the defense thereof other than reasonable costs of
investigation. No indemnifying party shall, without the written consent of the indemnified party,
effect the settlement or compromise of, or consent to the entry of any judgment with respect to,
any pending or threatened action or claim in respect of which indemnification or contribution may
be sought hereunder (whether or not the indemnified party is an actual or potential party to such
action or claim) unless such settlement, compromise or judgment (i) includes an unconditional
release of the indemnified party from all liability arising out of such action or claim and (ii)
does not include any statement as to or an admission of fault, culpability or a failure to act, by
or on behalf of any indemnified party.
(d) If the indemnification provided for in this Section 9 is unavailable to or insufficient to
hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses,
claims, damages or liabilities (or actions in respect thereof) referred to therein, then each
indemnifying party shall contribute to the amount paid or payable by such indemnified party as a
result of such losses, claims, damages or liabilities (or actions in respect thereof) in such
proportion as is appropriate to reflect the relative benefits received by the Company on the one
hand and the Underwriters on the other from the offering of the Shares. If, however, the
16
allocation provided by the immediately preceding sentence is not permitted by applicable law
or if the indemnified party failed to give the notice required under subsection (c) above, then
each indemnifying party shall contribute to such amount paid or payable by such indemnified party
in such proportion as is appropriate to reflect not only such relative benefits but also the
relative fault of the Company on the one hand and the Underwriters on the other in connection with
the statements or omissions which resulted in such losses, claims, damages or liabilities (or
actions in respect thereof), as well as any other relevant equitable considerations. The relative
benefits received by the Company on the one hand and the Underwriters on the other shall be deemed
to be in the same proportion as the total net proceeds from the offering (before deducting
expenses) received by the Company bear to the total underwriting discounts and commissions received
by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus.
The relative fault shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the Company on the one hand or the Underwriters on the
other and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission. The Company and the Underwriters agree that it would not be
just and equitable if contribution pursuant to this subsection (d) were determined by pro rata
allocation (even if the Underwriters were treated as one entity for such purpose) or by any other
method of allocation which does not take account of the equitable considerations referred to above
in this subsection (d). The amount paid or payable by an indemnified party as a result of the
losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this
subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to
contribute any amount in excess of the amount by which the total price at which the Shares
underwritten by it and distributed to the public were offered to the public exceeds the amount of
any damages which such Underwriter has otherwise been required to pay by reason of such untrue or
alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters’ obligations in this subsection (d) to contribute are several in proportion to their
respective underwriting obligations and not joint.
(e) The obligations of the Company under this Section 9 shall be in addition to any liability
which the Company may otherwise have and shall extend, upon the same terms and conditions, to each
person, if any, who controls any Underwriter within the meaning of the Securities Act and each
broker-dealer affiliate of any Underwriter; and the obligations of the Underwriters under this
Section 9 shall be in addition to any liability which the respective Underwriters may otherwise
have and shall extend, upon the same terms and conditions, to each officer and director of the
Company and to each person, if any, who controls the Company within the meaning of the Securities
Act.
10. (a) If any Underwriter shall default in its obligation to purchase the Shares which it
has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you
or another party or other parties to purchase such Shares on the terms contained herein. If within
thirty-six hours after such default by any Underwriter you do not arrange for the purchase of such
Shares, then the Company shall be entitled to a further period of thirty-six hours within which to
procure another party or other parties reasonably satisfactory to you to purchase such Shares on
such terms. In the event that, within the respective prescribed periods, you notify the Company
that you have so arranged for the purchase of such Shares, or the Company notifies you that it has
so arranged for the purchase of such Shares, you or the Company shall have the right to postpone
such Time of Delivery for a period of not more than seven days, in order to
17
effect whatever changes may thereby be made necessary in the Registration Statement or the
Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any
amendments or supplements to the Registration Statement or the Prospectus which in your opinion may
thereby be made necessary. The term “Underwriter” as used in this Agreement shall include any
person substituted under this Section with like effect as if such person had originally been a
party to this Agreement with respect to such Shares.
(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by you and the Company as provided in subsection (a) above, the
aggregate number of such Shares which remains unpurchased does not exceed one-eleventh of the
aggregate number of all the Shares to be purchased at such Time of Delivery, then the Company shall
have the right to require each non-defaulting Underwriter to purchase the number of shares which
such Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require
each non-defaulting Underwriter to purchase its pro rata share (based on the number of Shares which
such Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter or
Underwriters for which such arrangements have not been made; but nothing herein shall relieve a
defaulting Underwriter from liability for its default.
(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by you and the Company as provided in subsection (a) above, the
aggregate number of such Shares which remains unpurchased exceeds one-eleventh of the aggregate
number of all the Shares to be purchased at such Time of Delivery, or if the Company shall not
exercise the right described in subsection (b) above to require non-defaulting Underwriters to
purchase Shares of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect
to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company
to sell the Optional Shares) shall thereupon terminate, without liability on the part of any
non-defaulting Underwriter or the Company, except for the expenses to be borne by the Company and
the Underwriters as provided in Section 7 hereof and the indemnity and contribution agreements in
Section 9 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its
default.
11. The respective indemnities, agreements, representations, warranties and other statements
of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf
of them, respectively, pursuant to this Agreement, shall remain in full force and effect,
regardless of any investigation (or any statement as to the results thereof) made by or on behalf
of any Underwriter or any controlling person of any Underwriter, or the Company, or any officer or
director or controlling person of the Company, and shall survive delivery of and payment for the
Shares.
12. If this Agreement shall be terminated pursuant to Section 10 hereof, the Company shall not
then be under any liability to any Underwriter except as provided in Sections 7 and 9 hereof; but,
if for any other reason, any Shares are not delivered by or on behalf of the Company as provided
herein, the Company will reimburse the Underwriters through you for all out-of-pocket expenses
approved in writing by you, including fees and disbursements of counsel, reasonably incurred by the
Underwriters in making preparations for the purchase, sale and delivery of the Shares not so
delivered, but the Company shall then be under no further liability to any Underwriter except as
provided in Sections 7 and 9 hereof.
13. In all dealings hereunder, you shall act on behalf of each of the Underwriters, and the
parties hereto shall be entitled to act and rely upon any statement, request, notice or agreement
on behalf of any Underwriter made or given by you jointly or by Xxxxxxx, Xxxxx &
18
Co. and Citigroup Global Markets Inc. on behalf of you as the Representatives.
All statements, requests, notices and agreements hereunder shall be in writing, and if to the
Underwriters shall be delivered or sent by mail, telex or facsimile transmission to you as the
Representatives at c/o Citigroup Global Markets Inc., General Counsel, 000 Xxxxxxxxx Xxxxxx, Xxx
Xxxx, Xxx Xxxx 00000, Attention: General Counsel and c/o Goldman, Sachs & Co., 00 Xxxxx Xxxxxx,
00xx Xxxxx, Xxx Xxxx, Xxx Xxxx 00000, Attention: Registration Department; and if to the Company
shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company
set forth in the Registration Statement, Attention: Secretary; provided, however, that any notice
to an Underwriter pursuant to Section 9(c) hereof shall be delivered or sent by mail, telex or
facsimile transmission to such Underwriter at its address set forth in its Underwriters’
Questionnaire, or telex constituting such Questionnaire, which address will be supplied to the
Company by you upon request. Any such statements, requests, notices or agreements shall take effect
upon receipt thereof.
In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56
(signed into law October 26, 2001)), the underwriters are required to obtain, verify and record
information that identifies their respective clients, including the Company, which information may
include the name and address of their respective clients, as well as other information that will
allow the underwriters to properly identify their respective clients.
14. This Agreement shall be binding upon, and inure solely to the benefit of, the
Underwriters, the Company and, to the extent provided in Sections 8 and 10 hereof, the officers and
directors of the Company and each person who controls the Company or any Underwriter, and their
respective successors and assigns, and no other person shall acquire or have any right under or by
virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a
successor or assign by reason merely of such purchase.
15. Time shall be of the essence of this Agreement. As used herein, the term “business day”
shall mean any day when the Commission’s office in Washington, D.C. is open for business.
16. The Company acknowledges and agrees that (i) the purchase and sale of the Shares pursuant
to this Agreement is an arm’s-length commercial transaction between the Company, on the one hand,
and the several Underwriters, on the other, (ii) in connection therewith and with the process
leading to such transaction each Underwriter is acting solely as a principal and not the agent or
fiduciary of the Company, (iii) no Underwriter has assumed an advisory or fiduciary responsibility
in favor of the Company with respect to the offering contemplated hereby or the process leading
thereto (irrespective of whether such Underwriter has advised or is currently advising the Company
on other matters) or any other obligation to the Company except the obligations expressly set forth
in this Agreement and (iv) the Company has consulted its own legal and financial advisors to the
extent it deemed appropriate. The Company agrees that it will not claim that the Underwriters, or
any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or
similar duty to the Company, in connection with such transaction or the process leading thereto.
17. This Agreement supersedes all prior agreements and understandings (whether written or
oral) between the Company and the Underwriters, or any of them, with respect to the subject matter
hereof.
18. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York.
19
19. The Company and each of the Underwriters hereby irrevocably waives, to the fullest
extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby.
20. Notwithstanding anything herein to the contrary, the Company is authorized to disclose to any
persons U.S. federal and state tax treatment and tax structure of the potential transaction and all
materials of any kind (including tax opinions and other tax analyses) provided to the Company
relating to that treatment and structure, without the Underwriters imposing any limitation of any
kind. However, any information relating to the tax treatment and tax structure shall remain
confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any
person to comply with securities laws. For this purpose, “tax structure” is limited to any facts
that may be relevant to that treatment.”
20
If the foregoing is in accordance with your understanding, please sign and return to us
counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters,
this letter and such acceptance hereof shall constitute a binding agreement between each of the
Underwriters and the Company. It is understood that your acceptance of this letter on behalf of
each of the Underwriters is pursuant to the authority set forth in a form of Agreement among
Underwriters, the form of which shall be submitted to the Company for examination upon request, but
without warranty on your part as to the authority of the signers thereof.
Very truly yours, HUMAN GENOME SCIENCES, INC. |
||||
By: | /s/ H. Xxxxxx Xxxxxxx |
|||
Name: | H. Xxxxxx Xxxxxxx | |||
Title: | President & Chief Executive Officer |
Accepted as of the date hereof:
CITIGROUP GLOBAL MARKETS INC.
By: | /s/ Xxxxxxx X. Xxxxx (Citigroup Global Markets Inc.) |
XXXXXXX, SACHS & CO.
By: | /s/ Xxxxxxx, Xxxxx & Co. (Xxxxxxx, Xxxxx & Co.) |
For themselves and as Representatives of the
several Underwriters named in Schedule I hereto
several Underwriters named in Schedule I hereto
SCHEDULE I
Maximum Number | ||||||||
of Optional | ||||||||
Number of | Shares to be | |||||||
Shares | Purchased if Maximum | |||||||
Underwriter | to be Purchased | Option Exercised | ||||||
Citigroup Global Markets Inc.
|
9,286,000 | 1,392,900 | ||||||
Xxxxxxx, Sachs & Co.
|
9,286,000 | 1,392,900 | ||||||
Credit Suisse Securities (USA) LLC
|
2,321,500 | 348,225 | ||||||
X.X. Xxxxxx Securities Inc.
|
2,321,500 | 348,225 | ||||||
Total
|
23,215,000 | 3,482,250 | ||||||